Royal Philips announced today that its IQon Spectral CT now has increased potential thanks to a new diagnostic suite approved for the U.S. market.

By providing spectral capabilities within traditional CT applications, the Spectral Diagnostic Suite may unlock a new level of flexibility and clinical utility for the workhorse imaging modality.

Allowing clinicians to utilize the spectral information "on-demand" could mean having the ability to make better clinical decisions without disrupting workflow.

It may also reduce repeat imaging, as incidental findings can be explored in greater depth with the spectral data sets.

"Philips Spectral suite offers a new level of control for clinicians, allowing for segmentation on different energy levels, more detailed comparison between images, and advanced fusion capabilities, for diagnostic confidence," said Dr. Prabhakar Rajiah, assistant professor of radiology at the University Hospitals of Cleveland, UH Case Medical Center, Department of Radiology.

Rajiah collaborated with Philips on the development of the Spectral Diagnostic Suite.

The visual and analytical benefits of the Spectral Diagnostic Suite can be tapped into from a variety of different settings. According to a statement from Philips, the spectral data can be viewed from a reading room, a PACS system, or a remote location.

The IQon Spectral CT system itself received FDA approval in November of 2014.